How effective is Revumenib-Revuforj in melanoma?

Revuforj is an oral small molecule anti-cancer drug. It is the first selective inhibitor in international drug development to target the pathway related to the fusion of menin protein and KMT2A (MLL) gene. This mechanism has important clinical significance for patients with acute leukemia, especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement.

However, there is currently no evidence that revimenib is effective in the treatment of melanoma, and there are no relevant clinical trials showing that the drug can improve the survival outcomes of melanoma patients. Melanoma is a skin malignancy mainly caused by driver gene mutations such as BRAF, NRAS or KIT, and its treatment model focuses on BRAF/MEK inhibitors and immune checkpoint inhibitors. The target of Revimenib is not directly related to the molecular mechanism of melanoma, so the drug has not entered the routine treatment options for melanoma.

There has always been a trend in the forefront of drug research and development to explore cross-indication applications, but whether any drug can be expanded to new cancer indications must undergo rigorous clinical verification. At this stage, Revuforj's clinical trials and approval scope are focused on leukemias associated with KMT2A gene rearrangements, and do not involve solid tumors such as melanoma. For melanoma patients, the treatments recommended by international guidelines are still immunotherapy (such as PD-1 antibodies) and targeted therapy (such as dabrafenib, trametinib, etc.). Clinically, if a patient or family member sees Revimenid in a data search and expects it to be used for melanoma, they should understand that this is inappropriate.

In short, Revimenib has not been proven effective in melanoma, and it cannot replace existing standard treatments. Its research and application are still focused on hematological malignancies, especially acute leukemia caused by KMT2A rearrangement.

Reference materials:https://www.drugs.com/monograph/revumenib.html